Guay David R
Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota 55455, USA.
Consult Pharm. 2008 Feb;23(2):141-56. doi: 10.4140/tcp.n.2008.141.
To review the efficacy and tolerability profiles of quinine in nocturnal and dialysis-associated leg cramps and to examine potential alternative agents.
Selection and extraction: a MEDLINE/PubMed, English-language literature search from 1966 to the present using quinine, leg cramps, vitamin E, verapamil, muscle relaxants, gabapentin as search terms.
Quinine, an alkaloid originally isolated from the cinchona tree, has been used for many years to treat/prevent leg cramps. In the mid-1990s, the Food and Drug Administration (FDA) banned over-the-counter availability of quinine and marketing of prescription quinine products for leg cramps. In early 2007, FDA banned all prescription quinine products other than Qualaquin. FDA acted in this manner because of a perception that quinine is not effective for this condition and that its risk potential far exceeds its efficacy potential. Efficacy trials for quinine in leg cramps have numerous design flaws that have resulted in poor quality data, producing both positive and negative findings. Two meta-analyses have reached different conclusions. Superimposed on the questionable efficacy of quinine is the well-known toxicity profile of the drug, involving the hematologic, renal, neurologic, cardiac, and endocrine systems.
Are there any alternatives to quinine for leg cramps? Data are available supporting the potential efficacy of verapamil, gabapentin, carisoprodol, and orphenadrine in the general population, and vitamin E in the dialysis population. One or more of these agents should be tried before resorting to a time-limited (four- to six-week) trial of quinine for the treatment/prevention of leg cramps.
回顾奎宁治疗夜间腿部痉挛和透析相关性腿部痉挛的疗效及耐受性,并研究潜在的替代药物。
筛选与提取:通过使用奎宁、腿部痉挛、维生素E、维拉帕米、肌肉松弛剂、加巴喷丁作为检索词,对1966年至今的MEDLINE/PubMed英文文献进行检索。
奎宁是一种最初从金鸡纳树中分离出的生物碱,多年来一直用于治疗/预防腿部痉挛。在20世纪90年代中期,美国食品药品监督管理局(FDA)禁止非处方销售奎宁以及将处方奎宁产品用于腿部痉挛的营销。2007年初,FDA禁止了除硫酸奎宁(Qualaquin)之外的所有处方奎宁产品。FDA采取这一行动是因为认为奎宁对这种情况无效,且其潜在风险远远超过其疗效。奎宁治疗腿部痉挛的疗效试验存在众多设计缺陷,导致数据质量较差,得出了既有阳性也有阴性结果。两项荟萃分析得出了不同结论。在奎宁疗效存疑的同时,该药物还具有众所周知的毒性,涉及血液、肾脏、神经、心脏和内分泌系统。
对于腿部痉挛,奎宁有替代药物吗?有数据支持维拉帕米、加巴喷丁、卡立普多和奥芬那君在普通人群中以及维生素E在透析人群中的潜在疗效。在采用为期有限(四至六周)的奎宁试验来治疗/预防腿部痉挛之前,应先尝试使用这些药物中的一种或多种。